Caredx Inc (CDNA) Stock Price, Quote & News

Company Profile

CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offer...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 415 287 2300

Fax: 415 287 2450

Website: caredx.com

Address:

8000 Marina Boulevard, Brisbane, United States

ZacksResearch Mar. 12 at 5:07 PM

$CDNA just stepped deeper into AI for transplant medicine — and it could reshape how complex datasets are used. CareDx launched VANTx, an AI-driven cloud platform designed to turn complex transplant datasets into actionable insights, supporting both clinical research and real-world evidence. That’s a big push toward data-driven decision making in transplant care. 🧠 Discover what this launch could mean for the company’s strategy 👉 https://www.zacks.com/stock/news/2883251/caredx-introduces-vantx-ai-platform-for-complex-transplant-datasets?cid=sm-stocktwits-2-2883251-teaser-37200&ADID=SYND_STOCKTWITS_TWEET_2_2883251_TEASER_37200

0 · Reply

ZacksResearch Mar. 12 at 4:07 PM

$CDNA unveils VANTx but shares dip 8.5% since launch. What's happening? 🤔 Despite the recent setback, CDNA has rallied 26.8% over six months, outpacing the industry's 2.9% growth. The AI-driven platform strengthens its value proposition in transplant care, tapping into a $5.22 billion transplant diagnostics market by 2026. Opportunity or risk? Full analysis here 👉 https://www.zacks.com/stock/news/2883251/caredx-introduces-vantx-ai-platform-for-complex-transplant-datasets?cid=sm-stocktwits-2-2883251-body-37201&ADID=SYND_STOCKTWITS_TWEET_2_2883251_BODY_37201

0 · Reply

BillionerOfKing Mar. 10 at 1:04 PM

$CDNA Current Stock Price: $17.72 Contracts to trade: $17.5 CDNA Mar 20 2026 Call Entry: $1.84 Exit: $3.30 ROI: 79% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

11thestate Mar. 5 at 12:09 PM

$CDNA investors — there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/caredx-investor-settlement

0 · Reply

koditrump Mar. 4 at 8:00 PM

$CDNA $HIFS $ATV $TSLA $SPY Sell puts now!! 😆

0 · Reply

koditrump Mar. 3 at 1:22 PM

$APTV $CDNA $HIFS $FANG $TSLA

0 · Reply

GoldenTicket1 Feb. 26 at 6:20 PM

$CDNA BTIG maintains CareDx CDNA at Buy and raises the price target from $25 to $26

0 · Reply

erevnon Feb. 26 at 11:54 AM

BTIG maintains CareDx $CDNA at Buy and raises the price target from $25 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

GoldenTicket1 Feb. 25 at 11:21 AM

$CDNA Total Revenue: $108.4 million in Q4 2025, a 25% increase year over year. Testing Services Revenue: $78.4 million in Q4 2025, a 23% increase year over year. Testing Volume: Approximately 53,000 tests in Q4 2025, a 17% increase year over year. Average Revenue per Test: $1,480 in Q4 2025. Patient and Digital Solutions Revenue: $16.8 million in Q4 2025, a 47% increase year over year. Lab Products Revenue: $13.3 million in Q4 2025, a 17% increase year over year. Non-GAAP Gross Margin: 68.5% in Q4 2025. Adjusted EBITDA: $6.5 million in Q4 2025, a 34% decrease year over year. Cash Collections: $115.8 million in Q4 2025, a 37% increase year over year. Full Year 2025 Revenue: $379.8 million, a 14% increase year over year. Full Year Testing Services Revenue: $274.5 million, a 10% increase year over year. Full Year Testing Volume: Approximately 200,000 tests, a 14% increase year over year..... https://finance.yahoo.com/news/caredx-inc-cdna-q4-2025-050443525.html

0 · Reply

Estimize Feb. 25 at 11:03 AM

$CDNA reported -0.08 EPS and 108.39 revenue for Q4. http://www.estimize.com/intro/cdna?chart=historical&metric_name=eps&utm_content=CDNA&ut

0 · Reply

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

Feb 27, 2026, 4:01 PM EST - 13 days ago

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 25, 2026, 1:27 AM EST - 15 days ago

CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 5:15 PM EST - 16 days ago

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

Feb 24, 2026, 4:01 PM EST - 16 days ago

CareDx Announces Fourth Quarter and Full Year 2025 Financial Results

Feb 18, 2026, 8:00 AM EST - 22 days ago

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

Feb 15, 2026, 6:08 PM EST - 25 days ago

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

ABT ALKT CWAN DKNG DT ESTA EXAS

Feb 12, 2026, 4:24 PM EST - 4 weeks ago

CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript

Feb 12, 2026, 7:05 AM EST - 4 weeks ago

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

Feb 10, 2026, 4:01 PM EST - 4 weeks ago

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Feb 3, 2026, 7:05 AM EST - 5 weeks ago

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

Jan 27, 2026, 4:05 PM EST - 6 weeks ago

CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 12, 2026, 7:05 AM EST - 2 months ago

CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 7, 2026, 7:05 AM EST - 2 months ago

CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response

TXG

Dec 18, 2025, 5:00 PM EST - 3 months ago

CareDx Provides Notice of Proposed Derivative Settlement

Nov 24, 2025, 4:05 PM EST - 3 months ago

SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation

Nov 10, 2025, 8:00 AM EST - 4 months ago

CareDx to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 4 months ago

CareDx Announces New Precision Kidney Transplant Data and Product Innovations at ASN Kidney Week 2025

Nov 4, 2025, 10:16 PM EST - 4 months ago

CareDx, Inc (CDNA) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 4 months ago

CareDx Announces Third Quarter 2025 Financial Results

Oct 27, 2025, 7:05 AM EDT - 4 months ago

CareDx Announces Appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer

Oct 23, 2025, 4:05 PM EDT - 5 months ago

CareDx Announces Largest Landmark Study of Its Kind on Antibody Mediated Rejection in Heart Transplantation Published in Journal of the American College of Cardiology: Heart Failure

Oct 22, 2025, 4:01 PM EDT - 5 months ago

CareDx Announces Appointment of Suresh Gunasekaran to Board of Directors

Oct 21, 2025, 8:00 AM EDT - 5 months ago

CareDx to Report Third Quarter 2025 Financial Results on November 4, 2025

Oct 6, 2025, 7:05 AM EDT - 5 months ago

CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE® at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting

Sep 2, 2025, 4:01 PM EDT - 6 months ago

CareDx Issues Comment Letter on Draft LCD Policy

Aug 26, 2025, 1:08 PM EDT - 7 months ago

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

Aug 21, 2025, 4:01 PM EDT - 7 months ago

CareDx to Participate in Wells Fargo Healthcare Conference

Aug 6, 2025, 10:47 PM EDT - 7 months ago

CareDx, Inc (CDNA) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:57 PM EDT - 7 months ago

CareDx Announces Appointment of Nathan Smith as Chief Financial Officer

Aug 6, 2025, 4:01 PM EDT - 7 months ago

CareDx Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 12:56 PM EDT - 7 months ago

CareDx Announces Landmark KOAR Study Published in the American Journal of Transplantation

Jul 31, 2025, 4:01 PM EDT - 8 months ago

CareDx Announces Landmark Data in AI-Powered Transplant Diagnostics Showcased in Over 40 Abstracts and 16 Oral Presentations at the 2025 World Transplant Congress

Jul 23, 2025, 7:05 AM EDT - 8 months ago

CareDx to Report Second Quarter 2025 Financial Results

Jul 18, 2025, 8:00 AM EDT - 8 months ago

CareDx Announces Proposed Draft LCD That Affirms Surveillance Testing Coverage for Solid Organ Transplant Rejection

Jun 14, 2025, 7:23 AM EDT - 9 months ago

CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead

Jun 3, 2025, 4:30 PM EDT - 10 months ago

CareDx Announces Repurchase of 5% of Outstanding Shares

Apr 30, 2025, 8:39 PM EDT - 11 months ago

CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 4:05 PM EDT - 11 months ago

CareDx Reports First Quarter 2025 Results

Apr 29, 2025, 7:05 AM EDT - 11 months ago

CareDx Announces New Data on AlloSure Lung Presented at 2025 International Society for Heart and Lung Transplantation Meeting

Apr 24, 2025, 7:05 AM EDT - 11 months ago

CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting

Apr 21, 2025, 4:01 PM EDT - 11 months ago

CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Apr 8, 2025, 7:05 AM EDT - 1 year ago

CareDx to Report First Quarter 2025 Financial Results

Mar 28, 2025, 6:07 PM EDT - 1 year ago

CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

Mar 20, 2025, 7:00 AM EDT - 1 year ago

CI Global Asset Management Announces Securityholder Approval of Fund Mergers

Mar 14, 2025, 10:50 PM EDT - 1 year ago

CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA

Mar 11, 2025, 7:05 AM EDT - 1 year ago

CareDx Launches Two Expanded Indications for AlloSure Testing Services

Feb 26, 2025, 10:01 PM EST - 1 year ago

CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 1 year ago

CareDx Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 25, 2025, 7:05 AM EST - 1 year ago

CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict

ZacksResearch Mar. 12 at 5:07 PM

0 · Reply

ZacksResearch Mar. 12 at 4:07 PM

0 · Reply

BillionerOfKing Mar. 10 at 1:04 PM

0 · Reply

11thestate Mar. 5 at 12:09 PM

0 · Reply

koditrump Mar. 4 at 8:00 PM

$CDNA $HIFS $ATV $TSLA $SPY Sell puts now!! 😆

0 · Reply

koditrump Mar. 3 at 1:22 PM

$APTV $CDNA $HIFS $FANG $TSLA

0 · Reply

GoldenTicket1 Feb. 26 at 6:20 PM

$CDNA BTIG maintains CareDx CDNA at Buy and raises the price target from $25 to $26

0 · Reply

erevnon Feb. 26 at 11:54 AM

BTIG maintains CareDx $CDNA at Buy and raises the price target from $25 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

GoldenTicket1 Feb. 25 at 11:21 AM

0 · Reply

Estimize Feb. 25 at 11:03 AM

$CDNA reported -0.08 EPS and 108.39 revenue for Q4. http://www.estimize.com/intro/cdna?chart=historical&metric_name=eps&utm_content=CDNA&ut

0 · Reply

GoldenTicket1 Feb. 24 at 9:40 PM

$CDNA Claim rejection rates declined 60%!!!!

0 · Reply

StocktwitsEarnings Feb. 24 at 9:10 PM

$CDNA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 down -104.94% YoY • Reported revenue of $108.39M up 25.19% YoY • For the full year 2026, CareDx expects revenue to be in the range of $420M to $444M, including a $7.5M Medicare LCD impact, and adjusted EBITDA of $30M to $45M.

0 · Reply

GoldenTicket1 Feb. 24 at 9:05 PM

Earnings!! $CDNA https://share.google/qzxNwYQbtuMfBjDBa

0 · Reply

GoldenTicket1 Feb. 24 at 4:35 PM

$CDNA

0 · Reply

11thestate Feb. 24 at 12:41 PM

$CDNA has agreed to settle with investors over claims that it misled them about revenue quality and compliance with Medicare billing rules. Who’s eligible? Anyone who purchased $CDNA shares between April 30, 2020 and November 3, 2022. Do I need to sell my shares to qualify? No — you are eligible whether you sold your shares or still hold them. How much is the payout? The payout per share is $0.32 — but normally only about 25% of eligible investors file claims. If that trend holds, the effective payout could rise to approximately $1.28 per share. Can I still file? Late claims are being considered for compensation, subject to approval. When do payouts happen? Typically within 8–12 months after court approval of the settlement and processing of valid claims. To file your claim: https://11th.com/cases/caredx-investor-settlement

0 · Reply

GoldenTicket1 Feb. 24 at 11:22 AM

$CDNA Earnings day!!! 🚀🚀🚀🚀🚀

0 · Reply

OfficialStocktwitsUser Feb. 20 at 6:34 PM

$CDNA RSI: 40.68, MACD: -0.0552 Vol: 0.72, MA20: 19.94, MA50: 19.73 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

1 · Reply

CapitalParagon Feb. 20 at 2:01 PM

$CDNA CareDx provides transplant diagnostic solutions. Growth depends on procedure volumes. Reimbursement stability supports margins.

0 · Reply

ZacksResearch Feb. 16 at 5:11 PM

$CDNA ripping higher on a data win in AML & MDS. 🚀 AlloHeme showed early relapse detection in AML and MDS post HCT, fueling the stock’s move and supporting Transplant+ expansion into cell therapy markets. That’s a meaningful validation signal. See what this could mean for CareDx’s growth story 👉 https://www.zacks.com/stock/news/2869883/caredx-reports-positive-data-for-alloheme-in-aml-and-mds-post-hct?cid=sm-stocktwits-2-2869883-teaser-33699&ADID=SYND_STOCKTWITS_TWEET_2_2869883_TEASER_33699

0 · Reply

ZacksResearch Feb. 16 at 4:11 PM

$CDNA surged 65.6% in 6 months — is AlloHeme the key? 🚀 The new blood-based test detects AML/MDS relapse a median of 41 days earlier, with 85% sensitivity and 92% specificity, according to the ACROBAT study. This positions CDNA for growth in cell therapy and hematologic oncology. See what makes the investment case strong for CDNA 👉 https://www.zacks.com/stock/news/2869883/caredx-reports-positive-data-for-alloheme-in-aml-and-mds-post-hct?cid=sm-stocktwits-2-2869883-body-33678&ADID=SYND_STOCKTWITS_TWEET_2_2869883_BODY_33678

0 · Reply

GoldenTicket1 Feb. 13 at 2:59 PM

$CDNA. CareDx Expands “Transplant Plus” Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data https://finance.yahoo.com/news/caredx-expands-transplant-plus-cell-060902356.html

0 · Reply

GoldenTicket1 Feb. 13 at 2:58 PM

$CDNA CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy https://finance.yahoo.com/news/caredx-announces-clinical-validation-results-120500166.html

0 · Reply

Market Cap	878.35M
Revenue (ttm)	379.81M
Net Income (ttm)	-21.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	161.71
Profit Margin	-5.62%
Debt to Equity Ratio	0.00

Volume	656,700
Avg Vol	698,756
Day's Range	N/A - N/A
Shares Out	51.22M
Stochastic %K	6%
Beta	2.52
Analysts	Sell
Price Target	$24.80